Symbol
IKT on Nasdaq
Investment type
Equity - Shares of Stock
Class
Common Stock, $0.001 par value
Latest Disclosed Ownership
7.02M shares
Security Ownership
9.9%
Shares, Excluding Options vs Price
Value, Excluding Options

Fairmount Funds Management LLC ownership in Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value (IKT)

2025-02-14 - Fairmount Funds Management LLC has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 7.02M shares of Inhibikase Therapeutics, Inc. Common Stock, $0.001 par value (IKT). This represents 9.9% percent ownership of the company.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.